BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer. Our proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and important tumour biomarker in cancer. Our lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer. We are also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.